Anesthetic drugs are used while performing surgical procedures to control blood pressure, breathing, pain, heart rate, rhythm, and blood flow. Inhalational anesthesia is a chemical compound with anesthetic characteristics and is mainly used for sedation purposes and the induction of general anesthesia. These drugs are administered by the facemask and a tracheal tube attached to the vaporizer and another delivery system. Among inhalation anesthesia, isoflurane is the oldest and popular drug that is very efficient in low doses. As it eliminates risks and passed via the lungs to reduce hospital care costs, it preferred in case of impaired hepatic. It is anticipated to have a positive impact on market growth in coming years due to an increase in number of accidents and emergency cases.
COVID-19 Impact analysis
COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome corona virus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the inhalational anesthesia drugs market.
Top Impacting Factors
- Rise in number of road accidents and emergency incidences, surge in a predominance of many disorders such as respiratory diseases, gastrointestinal disorders, cancer, and genetic disorders, and increase in demand for surgical procedures drive the growth of the inhalational anesthesia drugs market.
- In addition, increase in healthcare expenditure; availability of skilled professionals; rise in R&D activities to improve quality of drugs; and launch of the novel developed drug in the market are some factors, which boost the market growth for inhalational anesthesia drugs.
- However, stringent regulatory approvals and side effects associated with these drugs hinder the market growth.
- Contrarily, favorable reimbursement policies and support from the government for using inhalation anesthetics present new pathways in the industry.
Market Trends
New product launches to flourish the market
In January 2019, Sandoz, a Novartis division, has launched Desflurane, Liquid for Inhalation, the first generic of Suprane in the U.S., as an inhalation agent. It is used for induction and maintenance of anesthesia for inpatient and outpatient surgery in adults, and for maintenance of anesthesia for inpatient and outpatient surgery in pediatric patients.
Key Benefits of the Report
- This study presents the analytical depiction of the inhalational anesthesia drugs industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the inhalational anesthesia drugs market share.
- The current market is quantitatively analyzed to highlight the inhalational anesthesia drugs market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed inhalational anesthesia drugs market analysis based on competitive intensity and how the competition will take shape in coming years
Questions answered in the inhalational anesthesia drugs Report
- Which are the leading players active in the inhalational anesthesia drugs market?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps?
- What is "Inhalational anesthesia drugs"?
- What is "Inhalational anesthesia drugs" Market prediction in the future?
- Who are the leading global players in the "Inhalational anesthesia drugs" Market?
- What are the current trends and predicted trends?
- What are the key benefits of the "Inhalational anesthesia drugs" Market report?
Inhalational Anesthesia Drugs Market Report Highlights
| Aspects | Details |
 By Product Type |
|
 By Application |
|
 By End User |
|
 By Region |
|
 Key Market Players | Jiangsu Hengrui Medicine Co. Ltd., Fresenius Kabi AG, Halocarbon Products Corporation, Lunan Pharmaceutical Group Co. Ltd., Piramal Enterprises Limited, Baxter International, AbbVie Inc., Hikima Pharmaceuticals PLC, Troikaa Pharmaceuticals Ltd |
Loading Table Of Content...
